ESSA Pharma Inc EPIX

Healthcare Biotechnology

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

NDAQ:EPIX - Post by User

ESSA Pharma Inc

Bullboard Posts

Post by SilentRiveron Feb 24, 2020 7:17am

114 Views

Post# 30724629

Insider buying

Filed 2020-02-20 17:50 Tx date 2020-02-20	$EPI ESSA Pharma Inc.	BERGER, FRANKLIN MILAN 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$270,000 +50,000 vol $5.40 each	442,410
Filed 2020-02-20 17:49 Tx date 2020-02-19	$EPI ESSA Pharma Inc.	BERGER, FRANKLIN MILAN 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$805,860 +150,000 vol $5.37 each	392,410
Filed 2020-02-20 17:47 Tx date 2020-02-19	$EPI ESSA Pharma Inc.	BERGER, FRANKLIN MILAN 4 - Director of Issuer Direct Ownership	Common Shares 10 - Acquisition or disposition in the public market	$158,764.05 +29,565 vol $5.37 each	242,410